Therapeutic | Imdevimab |
Target | SARS-CoV-2 Spike RBD |
Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS |
Light Chain | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL |
100% seqID Fv Structure | 6xdg [Fvs: CA] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6xdg [Fvs: CA] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | TBC |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2020 |
INN Year Recommended | None |
Companies Involved | TBC |
Conditions Approved | na |
Conditions Active | SARS-CoV-2 Infection |
Conditions Discontinued | na |
Notes |